Zobrazeno 1 - 10
of 25
pro vyhledávání: '"R. N. Fedorak"'
Autor:
N. Lycke, H. Kim, R. Vaicaitiene, M. Lee, J. Chang, H. Fukaya, K. Yamada, R. S. Gilbert, S. Kojima, L. M. Sollid, G. Seo, H. E. Steiner, S. Kimura, R. Chávez-Ramírez, H. Ohno, G. Duménil, Oliver Schulz, H. Okazawa, K. Tani, A. Givoni, P. N. T. Binh, D. Underhill, W. Agace, H. Tlaskalova-Hogenova, T. Kojima, M. Godínez-Victoria, Z. Xiang, P. Nilsson, E. Podack, E. L. Voronov, R. Kobayashi, R. Kvietkauskaite, V. Rivera-Aguilar, K. Soda, T. Kawara, R. Di Niro, N. Ohno, H. León-Chávez, M. T. Cantorna, F. Maruyama, M. Ebisawa, T. Nochi, P. Kim, G. S. Pontes, W. W. Agace, Y. Yoshikai, A. Shiokawa, S. Tsunoda, O. Liesenfeld, M. Yamamoto, T. Kamradt, A. A. Resendiz-Albor, T. Furuya, M. Ikutani, T. Saito, H. Tsutsui, H. Asanuma, T. Eguchi, A. Gómez-Anzures, Y. Yoshioka, I. Takahashi, L. Gram, S. Fukuda, K. E. A. Lundin, P. Marrack, M. Park, M. Sato-Hashimoto, J. Mrazek, S. Arita, M. Kweon, T. Cruz-Hernández, K. Kawana, T. Horikawa, Y. Fang, L. Larsson, H. Muta, C. Camarero, Y. Kinouchi, Y. Tsutsumi, K. Ramírez-Jiménez, M. Kverka, T. Obata, V. Soumelis, W. Ouyang, K. Adachi, S. Yamane, M. Deng, S. Park, H. Wang, M. Bono, D. Liu, R. R. Foshaug, A. Arakawa, K. Usui, Y. Kanazawa, P. Chiang, K. Hase, A. Shibuya, S. Miura, M. Yamazaki, Y. Kurashima, S. Ogawa, T. Kurita-Ochiai, J. Belacek, M. Jang, K. Nagano, M. L. Munoz-Roldan, M. Shimizu, B. C. Sydora, I. M. Arciniega-Martinez, X. Sun, A. Kormanovski-Kovsova, H. Kiyono, H. Kobayashi, I. Nakagawa, K. Kumagai, N. Ziv-Sokolovskaya, S. Kozuma, L. Gapin, P. N. Boyaka, E. Drago-Serrano, R. N. Fedorak, K. Shibata, T. Yoshikawa, D. You, A. De Andrés, Z. Venclikova, N. Itoh, R. Campos-Rodríguez, T. Nagatake, K. Kawano, N. Marín, L. J. DeTolla, Y. Minegishi, K. Shibuya, H. Yamada, H. Yan, Y. Iwakura, J. Bartova, S. Hori, J. Kopecny, M. Chien, K. Oda, Y. Murata, Z. Zakostelska, P. Michea, M. Sasaki, J. Kim, D. Musakhodjaeva, T. Iwamoto, M. H. Young, H. Ohnishi, C. Loddenkemper, T. Worbs, E. J. Albert, A. Kumanogoh, Y. Hanyu, K. Takatsu, T. Nomura, A. Resendiz-Albor, K. Sato, Y. Goto, G. Roy, M. J. Fial, R. Suzuki, M. Sugi, P. C. Wilson, K. Klimesova, M. Totsuka, T. Matozaki, S. Tahara-Hanaoka, K. Kadokura, Y. Abe, A. Bonnegarde, A. D. Keegan, K. Takagaki, S. Chang, M. Kawakami, P. Jiang, E. Stroblova, H. Kamada, Y. Jang, E. K. Persson, N. Takegahara, I. Nishimura, A. Gotoh, N. Zheng, H. Frøkiær, O. Frey, K. Beasley, R. M. White, K. Tomio, R. Iida, S. Kang, Y. Kawano, G. Rinot, S. Hachimura, H. Karasuyama, L. Luski, Y. Yoshizawa, J. Stamnaes, S. Kakuta, K. Tanabe, S. Mirete, R. Uchiyama, Tsuneyasu Kaisho, J. Kunisawa, T. Kouro, H. Cha, S. Kim, X. Liu, K. Nogawa, P. Rossmann, Y. Hamada, R. Apte, S. Honda, O. Pabst, Y. Fukuyama, S. Dotan, T. Hashizume, T. Kawashima, S. Sekine, T. Tobe, T. Shimosegawa, H. Kayamuro, M. Mauricas, Y. Taketani, I. D. Iliev, T. Fukaya, S. Bereswill, T. Mallevaey, H. Takagi, R. Hatano, F. Shamsiev, K. Kataoka, R. Sabat, N. Vynne, T. Fujii, D. Bruce, Y. Saito, N. Fayzullaeva, J. Jee, K. Fujihashi, N. M. Tsuji, Y. Supriatna, E. Smith, S. P. Chapoval, J. Jang, S. Wajima, T. Yokoyama, E. Jaensson, K. Maaetoft-Udsen, K. Wolk, M. M. Heimesaat, J. Pacheco-Yépez, L. Mesin, I. Arciniega-Martínez, H. Iwamura
Publikováno v:
International Immunology. 22:iv9-iv17
Publikováno v:
Canadian Journal of Physiology and Pharmacology. 74:1294-1301
Publikováno v:
Alimentary pharmacologytherapeutics. 34(2)
Infliximab is a chimeric monoclonal antibody to tumour necrosis factor alpha (TNFα) with efficacy in inducing and maintaining remission of inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis and psoriasis. Infliximab is generall
Autor:
A W G, Waugh, S, Garg, K, Matic, L, Gramlich, C, Wong, D C, Sadowski, M, Millan, R, Bailey, D, Todoruk, R, Cherry, C W, Teshima, L, Dieleman, R N, Fedorak
Publikováno v:
Alimentary pharmacologytherapeutics. 32(9)
Tumour necrosis factor-blockade with infliximab has advanced the treatment of Crohn's disease. While infliximab is efficacious, it remains to be determined whether patients who enter clinical remission with an anti-tumour necrosis factor therapy can
Publikováno v:
Alimentary pharmacologytherapeutics. 32(4)
Aliment Pharmacol Ther 2010; 32: 522-528 Summary Background Randomized, controlled trials have demonstrated that anti-TNF agents are efficacious in inducing remission in cases of Crohn's disease and ulcerative colitis. However, response rates for ant
Publikováno v:
The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique. 8(4)
Crohn's disease is a chronic inflammatory disorder of the gastrointestinal tract. From the perspective of the patient, symptoms of the disease significantly impair quality of life and interfere with activities of daily living. Conventional medical tr
Autor:
R N, Fedorak
Publikováno v:
Canadian journal of gastroenterology = Journal canadien de gastroenterologie. 15(6)
Autor:
S, Schreiber, R N, Fedorak, O H, Nielsen, G, Wild, C N, Williams, S, Nikolaus, M, Jacyna, B A, Lashner, A, Gangl, P, Rutgeerts, K, Isaacs, S J, van Deventer, J C, Koningsberger, M, Cohard, A, LeBeaut, S B, Hanauer
Publikováno v:
Gastroenterology. 119(6)
Interleukin (IL)-10 is a cytokine with potent anti-inflammatory properties. We investigated the safety and efficacy of different doses of human recombinant (rhu)IL-10 in patients with Crohn's disease (CD).A prospective, multicenter, double-blind, pla
Autor:
B G, Feagan, R N, Fedorak, E J, Irvine, G, Wild, L, Sutherland, A H, Steinhart, G R, Greenberg, J, Koval, C J, Wong, M, Hopkins, S B, Hanauer, J W, McDonald
Publikováno v:
The New England journal of medicine. 342(22)
Patients with Crohn's disease often have relapses. Better treatments are needed for the maintenance of remission. Although methotrexate is an effective short-term treatment for Crohn's disease, its role in maintaining remissions is not known.We condu
Publikováno v:
Alimentary pharmacologytherapeutics. 13(12)
Despite a decreased incidence of ulcer disease and improvements in the management of acute upper gastrointestinal (GI) bleeding, mortality remains at about 6-7%. Although endoscopic haemostatic therapy has been demonstrated to be the mainstay of mana